Idorsia Pharmaceuticals Ltd (IDRSF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the IdleCyfl Year 2024 Financial Results webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference has been recorded. I would now like to hand the conference over to your first speaker today. Andrew Jones, Head of Corporate Communications. Please go ahead. Thank you, Sonia. Good afternoon, good morning, everyone, and welcome to our webcast to discuss the 2024 Financial Results. On the call today, we have our CEO, Andre Muller, our President of the UCAN region, Benjamin Limahl, our President of US, Michael Moy, joining us in this capacity for the first time since the departure of Tosh, our Chief Scientific Officer, Martin Closell, and our Chief Financial Officer, Arno Grunewald. Then joining us for the Q&A session, we have our Group General Counsel, Julian Gander, in case of questions related to the recently announced agreement. So a lot to get through today. Next slide. Before handing over, I need to remind everyone that we will be making forward-looking statements. You have therefore been appropriately warned about the risks and opportunities of investing in Eidosia shares. With that, I hand over to Andre for his introductory remarks. Next slide. Yeah, thank you, Andrew. Good afternoon, or good morning, everyone, and thank you for joining the call today. Before going into the 2024 highlights, let's deal with the elephant in the room, the envisaged out-licensing agreement for our ...